Alliance Global Partners analyst Ben Haynor lowered the firm’s price target on Motus GI Holdings to $1.35 from $1.65 and keeps a Buy rating on the shares post the Q2 report. The reduction stems from the increased share count due to the recent financing transaction, the analyst tells investors in a research note. The firm thinks value remains for equity holders given the large potential market for Motus GI’s products and the strong clinical data supporting Pure-V.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MOTS:
- Motus GI Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Motus GI Holdings reports Q2 EPS (40c), consensus (61c)
- Motus GI Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of its Pure-Vu® EVS System
- Motus GI receives approval from Israeli MOH to initiate sales of Pure-Vu
- Motus GI announces purchase agreement for Pure-Vu System from Banner Desert